Argano Christiano, Priola Laura, Manno Francesco, Corrao Salvatore
Department of Internal Medicine, National Relevance and High Specialization Hospital Trust ARNAS Civico, Di Cristina, Benfratelli, 90127 Palermo, Italy.
Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy.
Biomedicines. 2024 Apr 18;12(4):900. doi: 10.3390/biomedicines12040900.
Despite the advent of innovative therapies in the treatment of diabetes, ever-increasing awareness is still directed to the role of insulin since it has continued to be at the centre of diabetes therapy for decades, as a therapeutic integration of innovative agents in type 2 diabetes mellitus (T2DM), as the only replacement therapy in type 1 diabetes mellitus (T1DM) and also in gestational diabetes. In this context, the study of molecules such as weekly basal insulins, both for their technological and pharmacodynamic innovation and their manageability and undoubted benefits in compliance with drug therapy, can only be a turning point in diabetes and for all its phenotypes. This review aims to provide insight into the knowledge of basal weekly insulins and their use in type 1 and 2 diabetes mellitus by examining their safety, efficacy, manageability and increased therapeutic compliance.
尽管糖尿病治疗领域出现了创新疗法,但人们对胰岛素作用的关注度仍在不断提高,因为几十年来胰岛素一直是糖尿病治疗的核心,它是2型糖尿病(T2DM)中创新药物的治疗整合剂,是1型糖尿病(T1DM)以及妊娠期糖尿病的唯一替代疗法。在这种背景下,对每周一次基础胰岛素等分子的研究,无论是从其技术和药效学创新,还是从其在药物治疗依从性方面的可管理性及无疑的益处来看,都必然会成为糖尿病及其所有表型治疗的一个转折点。本综述旨在通过研究基础每周一次胰岛素的安全性、有效性、可管理性及提高的治疗依从性,深入了解其相关知识以及在1型和2型糖尿病中的应用。